Vera Therapeutics Inc. (VERA) IPO Opens, Trades Higher

Today's IPO for Vera Therapeutics Inc. (NASDAQ: VERA) opened for trading earlier at $11.41 after pricing 4,350,000 shares of its Class A common stock at a price to the public of $11.00 per share. Shares have continued higher to $12.10.

Jefferies LLC, Cowen and Company, LLC, and Evercore Group L.L.C. are acting as active joint book-running managers for the offering.

Vera Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Vera’s lead program is atacicept, a fusion protein that is in development for IgA nephropathy, a disease with high unmet medical need and no approved therapies. In addition, Vera is evaluating additional diseases where atacicept’s reduction of autoantibodies may prove medically useful, including lupus nephritis (LN), a severe renal manifestation of systemic lupus erythematosus (SLE).

You May Also Be Interested In

• CoVolt Power files for proposed IPO
• Array shifts to integrated solar platform with record orderbook
• UDynamics files for Nasdaq IPO of 5.6 million shares at $5-$7 per share